Myeloma Paper of the Day, August 31st, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Updated KarMMa-3 analyses shows Ide-cel improved median PFS vs. standard regimens (13.8 vs. 4.4 months; HR 0.49; 95% CI 0.38-0.63) and ORR (71% vs. 42%; complete response, 44% vs. 5%) with no new safety signals.”
Source: Robert Orlowski/X
Authors: Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott R. Solomon, Ingerid Weum Abrahamsen, Rachid C Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesus G. Berdeja, Sergio A Giralt, Anna Truppel-Hartmann, Yanping Chen, Xiaobo Zhong, Fan Wu, Julia Piasecki, Laurie Eliason, Devender S. Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa-Mckiver, Paula Rodriguez-Otero.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.
